Clinical Trial Update: An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 open-label, randomized bioequivalence study comparing oral and intravenous rolapitant for chemotherapy-induced n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• VARUBI (rolapitant)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 1 | Status: COMPLETED